1
|
Steinberg C, Dognin N, Sodhi A, Champagne C, Staples JA, Champagne J, Laksman ZW, Sarrazin JF, Bennett MT, Plourde B, Deyell MW, Andrade JG, Roy K, Yeung-Lai-Wah JA, Hawkins NM, Mondésert B, Blier L, Nault I, O'Hara G, Krahn AD, Philippon F, Chakrabarti S. DREAM-ICD-II Study. Circulation 2022; 145:742-753. [PMID: 34913361 DOI: 10.1161/circulationaha.121.056471] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Regulatory authorities of most industrialized countries recommend 6 months of private driving restriction after implantation of a secondary prevention implantable cardioverter-defibrillator (ICD). These driving restrictions result in significant inconvenience and social implications. This study aimed to assess the incidence rate of appropriate device therapies in contemporary recipients of a secondary prevention ICD. METHODS This retrospective study at 3 Canadian tertiary care centers enrolled consecutive patients with new secondary prevention ICD implants between 2016 and 2020. RESULTS For a median of 760 days (324, 1190 days), 721 patients were followed up. The risk of recurrent ventricular arrhythmia was highest during the first 3 months after device insertion (34.4%) and decreased over time (10.6% between 3 and 6 months, 11.7% between 6 and 12 months). The corresponding incidence rate per 100 patient-days was 0.48 (95% CI, 0.35-0.64) at 90 days, 0.28 (95% CI, 0.17-0.45) at 180 days, and 0.21 (95% CI, 0.13-0.33) between 181 and 365 days after ICD insertion (P<0.001). The cumulative incidence of arrhythmic syncope resulting in sudden cardiac incapacitation was 1.8% within the first 90 days and subsequently dropped to 0.4% between 91 and 180 days (P<0.001) after ICD insertion. CONCLUSIONS The incidence rate of appropriate therapies resulting in sudden cardiac incapacitation in contemporary recipients of a secondary prevention ICD is much lower than previously reported and declines significantly after the first 3 months. Lowering driving restrictions to 3 months after the index cardiac event seems safe, and revision of existing guidelines should be considered in countries still adhering to a 6-month period. Existing restrictions for private driving after implantation of a secondary prevention ICD should be reconsidered.
Collapse
Affiliation(s)
- Christian Steinberg
- Institut universitaire de cardiologie et pneumologie de Québec, Quebec, Canada (C.S., N.D., C.C., J.C., J.-F.S., B.P., K.R., L.B., I.N., G.O., F.P.)
| | - Nicolas Dognin
- Institut universitaire de cardiologie et pneumologie de Québec, Quebec, Canada (C.S., N.D., C.C., J.C., J.-F.S., B.P., K.R., L.B., I.N., G.O., F.P.)
| | - Amit Sodhi
- Centre for Cardiovascular Innovation, Division of Cardiology (A.S., Z.L., M.B., M.W.D., J.G.A., J.A.Y.-L.-W., N.M.H., A.D.K., S.C.), University of British Columbia, Vancouver, Canada
- Department of Medicine (A.S., J.A.S., Z.L., M.B., M.W.D., J.G.A., J.A.Y.-L.W., N.M.H., A.D.K., S.C.), University of British Columbia, Vancouver, Canada
| | - Catherine Champagne
- Institut universitaire de cardiologie et pneumologie de Québec, Quebec, Canada (C.S., N.D., C.C., J.C., J.-F.S., B.P., K.R., L.B., I.N., G.O., F.P.)
| | - John A Staples
- Department of Medicine (A.S., J.A.S., Z.L., M.B., M.W.D., J.G.A., J.A.Y.-L.W., N.M.H., A.D.K., S.C.), University of British Columbia, Vancouver, Canada
- Centre for Clinical Epidemiology and Evaluation, Vancouver, British Columbia, Canada (J.A.S.)
| | - Jean Champagne
- Institut universitaire de cardiologie et pneumologie de Québec, Quebec, Canada (C.S., N.D., C.C., J.C., J.-F.S., B.P., K.R., L.B., I.N., G.O., F.P.)
| | - Zachary W Laksman
- Centre for Cardiovascular Innovation, Division of Cardiology (A.S., Z.L., M.B., M.W.D., J.G.A., J.A.Y.-L.-W., N.M.H., A.D.K., S.C.), University of British Columbia, Vancouver, Canada
- Department of Medicine (A.S., J.A.S., Z.L., M.B., M.W.D., J.G.A., J.A.Y.-L.W., N.M.H., A.D.K., S.C.), University of British Columbia, Vancouver, Canada
| | - Jean-François Sarrazin
- Institut universitaire de cardiologie et pneumologie de Québec, Quebec, Canada (C.S., N.D., C.C., J.C., J.-F.S., B.P., K.R., L.B., I.N., G.O., F.P.)
| | - Matthew T Bennett
- Centre for Cardiovascular Innovation, Division of Cardiology (A.S., Z.L., M.B., M.W.D., J.G.A., J.A.Y.-L.-W., N.M.H., A.D.K., S.C.), University of British Columbia, Vancouver, Canada
- Department of Medicine (A.S., J.A.S., Z.L., M.B., M.W.D., J.G.A., J.A.Y.-L.W., N.M.H., A.D.K., S.C.), University of British Columbia, Vancouver, Canada
| | - Benoit Plourde
- Institut universitaire de cardiologie et pneumologie de Québec, Quebec, Canada (C.S., N.D., C.C., J.C., J.-F.S., B.P., K.R., L.B., I.N., G.O., F.P.)
| | - Marc W Deyell
- Centre for Cardiovascular Innovation, Division of Cardiology (A.S., Z.L., M.B., M.W.D., J.G.A., J.A.Y.-L.-W., N.M.H., A.D.K., S.C.), University of British Columbia, Vancouver, Canada
- Department of Medicine (A.S., J.A.S., Z.L., M.B., M.W.D., J.G.A., J.A.Y.-L.W., N.M.H., A.D.K., S.C.), University of British Columbia, Vancouver, Canada
| | - Jason G Andrade
- Centre for Cardiovascular Innovation, Division of Cardiology (A.S., Z.L., M.B., M.W.D., J.G.A., J.A.Y.-L.-W., N.M.H., A.D.K., S.C.), University of British Columbia, Vancouver, Canada
- Department of Medicine (A.S., J.A.S., Z.L., M.B., M.W.D., J.G.A., J.A.Y.-L.W., N.M.H., A.D.K., S.C.), University of British Columbia, Vancouver, Canada
- Montreal Heart Institute, Department of Medicine, Université de Montréal, Montreal, Quebec, Canada (J.G.A., B.M.)
| | - Karine Roy
- Institut universitaire de cardiologie et pneumologie de Québec, Quebec, Canada (C.S., N.D., C.C., J.C., J.-F.S., B.P., K.R., L.B., I.N., G.O., F.P.)
| | - John A Yeung-Lai-Wah
- Centre for Cardiovascular Innovation, Division of Cardiology (A.S., Z.L., M.B., M.W.D., J.G.A., J.A.Y.-L.-W., N.M.H., A.D.K., S.C.), University of British Columbia, Vancouver, Canada
- Department of Medicine (A.S., J.A.S., Z.L., M.B., M.W.D., J.G.A., J.A.Y.-L.W., N.M.H., A.D.K., S.C.), University of British Columbia, Vancouver, Canada
| | - Nathaniel M Hawkins
- Centre for Cardiovascular Innovation, Division of Cardiology (A.S., Z.L., M.B., M.W.D., J.G.A., J.A.Y.-L.-W., N.M.H., A.D.K., S.C.), University of British Columbia, Vancouver, Canada
- Department of Medicine (A.S., J.A.S., Z.L., M.B., M.W.D., J.G.A., J.A.Y.-L.W., N.M.H., A.D.K., S.C.), University of British Columbia, Vancouver, Canada
| | - Blandine Mondésert
- Montreal Heart Institute, Department of Medicine, Université de Montréal, Montreal, Quebec, Canada (J.G.A., B.M.)
| | - Louis Blier
- Institut universitaire de cardiologie et pneumologie de Québec, Quebec, Canada (C.S., N.D., C.C., J.C., J.-F.S., B.P., K.R., L.B., I.N., G.O., F.P.)
| | - Isabelle Nault
- Institut universitaire de cardiologie et pneumologie de Québec, Quebec, Canada (C.S., N.D., C.C., J.C., J.-F.S., B.P., K.R., L.B., I.N., G.O., F.P.)
| | - Gilles O'Hara
- Institut universitaire de cardiologie et pneumologie de Québec, Quebec, Canada (C.S., N.D., C.C., J.C., J.-F.S., B.P., K.R., L.B., I.N., G.O., F.P.)
| | - Andrew D Krahn
- Centre for Cardiovascular Innovation, Division of Cardiology (A.S., Z.L., M.B., M.W.D., J.G.A., J.A.Y.-L.-W., N.M.H., A.D.K., S.C.), University of British Columbia, Vancouver, Canada
- Department of Medicine (A.S., J.A.S., Z.L., M.B., M.W.D., J.G.A., J.A.Y.-L.W., N.M.H., A.D.K., S.C.), University of British Columbia, Vancouver, Canada
| | - François Philippon
- Institut universitaire de cardiologie et pneumologie de Québec, Quebec, Canada (C.S., N.D., C.C., J.C., J.-F.S., B.P., K.R., L.B., I.N., G.O., F.P.)
| | - Santabhanu Chakrabarti
- Centre for Cardiovascular Innovation, Division of Cardiology (A.S., Z.L., M.B., M.W.D., J.G.A., J.A.Y.-L.-W., N.M.H., A.D.K., S.C.), University of British Columbia, Vancouver, Canada
- Department of Medicine (A.S., J.A.S., Z.L., M.B., M.W.D., J.G.A., J.A.Y.-L.W., N.M.H., A.D.K., S.C.), University of British Columbia, Vancouver, Canada
| |
Collapse
|
2
|
Bjerre J, Rosenkranz SH, Schou M, Jøns C, Philbert BT, Larroudé C, Nielsen JC, Johansen JB, Riahi S, Melchior TM, Torp-Pedersen C, Hlatky M, Gislason G, Ruwald AC. Driving following defibrillator implantation: a nationwide register-linked survey study. Eur Heart J 2021; 42:3529-3537. [PMID: 33954626 DOI: 10.1093/eurheartj/ehab253] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/26/2020] [Revised: 03/04/2021] [Accepted: 04/13/2021] [Indexed: 01/09/2023] Open
Abstract
AIMS Patients are restricted from driving following implantable cardioverter defibrillator (ICD) implantation or shock. We sought to investigate how many patients are aware of, and adhere to, the driving restrictions, and what proportion experience an ICD shock or other cardiac symptoms while driving. METHODS AND RESULTS We performed a nationwide survey of all living Danish residents 18 years or older who received a first-time ICD between 2013 and 2016 (n = 3913) and linked their responses with nationwide registers. Of 2741 respondents (47% primary prevention, 83% male, median age 67 years), 2513 (92%) held a valid driver's license at ICD implantation, 175 (7%) of whom had a license for professional driving. Many drivers were unaware of driving restrictions: primary prevention 58%; secondary prevention 36%; post-appropriate shock 28%; professional drivers 55%. Almost all (94%) resumed non-professional driving after ICD implantation, more than one-third during the restricted period; 35% resumed professional driving. During a median follow-up of 2.3 years, 5 (0.2%) reported receiving an ICD shock while driving, one of which resulted in a traffic accident. The estimated risk of harm was 0.0002% per person-year. CONCLUSION In this nationwide study, many ICD patients were unaware of driving restrictions, and more than one third resumed driving during a driving restriction period. However, the rate of reported ICD shocks while driving was very low.
Collapse
Affiliation(s)
- Jenny Bjerre
- Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Gentofte Hospitalsvej 6, 3rd Floor, Hellerup 2900, Denmark.,Department of Cardiology, Copenhagen University Hospital Bispebjerg and Frederiksberg, Bispebjerg Bakke 23, 2400 Copenhagen, Denmark
| | - Simone Hofman Rosenkranz
- Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Gentofte Hospitalsvej 6, 3rd Floor, Hellerup 2900, Denmark
| | - Morten Schou
- Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Gentofte Hospitalsvej 6, 3rd Floor, Hellerup 2900, Denmark
| | - Christian Jøns
- Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark
| | - Berit Thornvig Philbert
- Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark
| | - Charlotte Larroudé
- Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Gentofte Hospitalsvej 6, 3rd Floor, Hellerup 2900, Denmark
| | - Jens Cosedis Nielsen
- Department of Clinical Medicine, Aarhus University Hospital, Palle Juul-Jensens Blvd. 82, 8200 Aarhus, Denmark
| | - Jens Brock Johansen
- Department of Cardiology, Odense University Hospital, J.B. Winsløws Vej 4, 5000 Odense C, Denmark
| | - Sam Riahi
- Department of Cardiology, Aalborg University Hospital, Hobrovej 18-22, 9200 Aalborg, Denmark
| | - Thomas Maria Melchior
- Department of Cardiology, Zealand University Hospital, Sygehusvej 10, 4000 Roskilde, Denmark
| | - Christian Torp-Pedersen
- Department of Cardiology and Clinical Research, Nordsjællands Hospital, Dyrehavevej 29, 3400 Hillerød, Denmark
| | - Mark Hlatky
- Department of Medicine, Stanford University School of Medicine, 615 Crothers Way Encina Commons, Stanford, CA 94305, USA
| | - Gunnar Gislason
- Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Gentofte Hospitalsvej 6, 3rd Floor, Hellerup 2900, Denmark.,Department of Cardiovascular Epidemiology and Research, The Danish Heart Foundation, Vognmagergade 7, 1120 Copenhagen, Denmark
| | - Anne-Christine Ruwald
- Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Gentofte Hospitalsvej 6, 3rd Floor, Hellerup 2900, Denmark.,Department of Cardiology, Zealand University Hospital, Sygehusvej 10, 4000 Roskilde, Denmark
| |
Collapse
|
4
|
Steinberg C, Cheung CC, Wan D, Sodhi A, Claros S, Staples JA, Philippon F, Laksman Z, Sarrazin JF, Bennett M, Plourde B, Deyell MW, Andrade JG, Roy K, Yeung-Lai-Wah JA, Molin F, Hawkins NM, Blier L, Nault I, O'Hara G, Krahn AD, Champagne J, Chakrabarti S. Driving Restrictions and Early Arrhythmias in Patients Receiving a Primary-Prevention Implantable Cardioverter-Defibrillator (DREAM-ICD) Study. Can J Cardiol 2020; 36:1269-1277. [PMID: 32474110 DOI: 10.1016/j.cjca.2020.05.029] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2020] [Revised: 05/19/2020] [Accepted: 05/20/2020] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Current guidelines recommend 4 weeks of private driving restriction after implantation of a primary-prevention implantable cardioverter-defibrillator (ICD). These driving restrictions result in significant inconvenience and social implications. Advances in medical treatment and ICD programming have lowered the overall rate of device therapies. The objective of this study was to assess the incidence of ICD therapies at 30, 60, and 180 days after implantation. METHODS Driving Restrictions and Early Arrhythmias in Patients Receiving a Primary-Prevention Implantable Cardioverter-Defibrillator (DREAM-ICD) was a retrospective cohort study conducted at 2 Canadian university centres enrolling patients with new implantation of a primary-prevention ICD. Device programming was standardised according to current guidelines. A total of 803 patients were enrolled. RESULTS The cumulative rates of appropriate ICD therapies at 30, 60, and 180 days were 0.12%, 0.50%, and 0.75%, respectively. There was no syncope during the first 6 months. The median duration to the first appropriate ICD therapy was 208 (range 23-1109) days after implantation. The rate of inappropriate ICD therapies at 30 days was only 0.2%. Overall, < 13.6% of all appropriate ICD therapies occurred within the first 6 months after implantation. CONCLUSIONS The rate of appropriate ICD therapies within the first 30 days after device insertion is extremely low in contemporary primary prevention cohorts with guideline-concordant device programming. There was no increased risk for ventricular arrhythmia early after ICD insertion. The results of DREAM-ICD suggest the need for a revision of the existing driving restrictions for primary-prevention ICD recipients.
Collapse
Affiliation(s)
- Christian Steinberg
- Institut Universitaire de Cardiologie et Pneumologie de Québec, Québec, Québec, Canada.
| | - Christopher C Cheung
- Heart Rhythm Services, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada
| | - Darryl Wan
- Heart Rhythm Services, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada
| | - Amit Sodhi
- Heart Rhythm Services, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada
| | - Sebastian Claros
- Institut Universitaire de Cardiologie et Pneumologie de Québec, Québec, Québec, Canada
| | - John A Staples
- Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Centre for Clinical Epidemiology and Evaluation, Vancouver, British Columbia, Canada
| | - François Philippon
- Institut Universitaire de Cardiologie et Pneumologie de Québec, Québec, Québec, Canada
| | - Zachary Laksman
- Heart Rhythm Services, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada
| | | | - Matthew Bennett
- Heart Rhythm Services, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada
| | - Benoit Plourde
- Institut Universitaire de Cardiologie et Pneumologie de Québec, Québec, Québec, Canada
| | - Marc W Deyell
- Heart Rhythm Services, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada
| | - Jason G Andrade
- Heart Rhythm Services, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada
| | - Karine Roy
- Institut Universitaire de Cardiologie et Pneumologie de Québec, Québec, Québec, Canada
| | - John A Yeung-Lai-Wah
- Heart Rhythm Services, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada
| | - Franck Molin
- Institut Universitaire de Cardiologie et Pneumologie de Québec, Québec, Québec, Canada
| | - Nathaniel M Hawkins
- Heart Rhythm Services, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada
| | - Louis Blier
- Institut Universitaire de Cardiologie et Pneumologie de Québec, Québec, Québec, Canada
| | - Isabelle Nault
- Institut Universitaire de Cardiologie et Pneumologie de Québec, Québec, Québec, Canada
| | - Gilles O'Hara
- Institut Universitaire de Cardiologie et Pneumologie de Québec, Québec, Québec, Canada
| | - Andrew D Krahn
- Heart Rhythm Services, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada
| | - Jean Champagne
- Institut Universitaire de Cardiologie et Pneumologie de Québec, Québec, Québec, Canada
| | - Santabhanu Chakrabarti
- Heart Rhythm Services, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada.
| |
Collapse
|
7
|
Bjerre J, Rosenkranz SH, Christensen AM, Schou M, Jøns C, Gislason G, Ruwald AC. Driving following defibrillator implantation: development and pilot results from a nationwide questionnaire. BMC Cardiovasc Disord 2018; 18:212. [PMID: 30458722 PMCID: PMC6245910 DOI: 10.1186/s12872-018-0949-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2018] [Accepted: 11/08/2018] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Implantable cardioverter defibrillator (ICD) implantation is associated with driving restrictions which may have profound effects on the patient's life. However, there is limited patient-reported data on the information given about driving restrictions, the adherence to the restrictions, the incidence of arrhythmic symptoms while driving, and the driving restrictions' effect on ICD patients' daily life and quality of life factors. A specific questionnaire was designed to investigate these objectives, intended for use in a nationwide ICD cohort. METHODS The conceptual framework based on literature review and expert opinion was refined in qualitative semi-structured focus group interviews with ten ICD patients. Content validity was pursued through pre-testing, including expert review and 28 cognitive interviews with patients at all ICD implanting centres in Denmark. Finally, the Danish Pacemaker and ICD registry was used to randomly select 50 ICD patients with a first-time implantation between January 1, 2013 and November 30, 2016 for pilot testing, followed by a test-retest on 25 respondents. Test-retest agreement was assessed using kappa statistics or intraclass correlation coefficients. RESULTS The pilot test achieved a response rate of 78%, whereof the majority were web-based (69%). Only 49% stated they had been informed about any driving restrictions after ICD implantation, whereas the number was 75% after appropriate ICD shock. Among respondents, 95% had resumed private driving, ranging from 1 to 90 days after ICD implantation. In those informed of a significant (≥ 1 month) driving ban, 55% stated the driving restrictions had impeded with daily life, especially due to limitations in maintaining employment or getting to/from work and 25% admitted they had knowingly been driving during the restricted period. There were six episodes of dizziness or palpitations not necessitating stopping the vehicle. Test-retest demonstrated good agreement of questionnaire items, with 69% of Kappa coefficients above 0.60. CONCLUSIONS We have developed a comprehensive questionnaire on ICD patients' perspective on driving. Pre-testing and pilot testing demonstrated good content validity, feasible data collection methods, and a robust response rate. Thus, we believe the final questionnaire, distributed to almost 4000 ICD patients, will capture essential evidence to help inform driving guidelines in this population.
Collapse
Affiliation(s)
- Jenny Bjerre
- Department of Cardiology, Cardiovascular Research, Copenhagen University Hospital Herlev-Gentofte, Kildegaardsvej 28, 2900, Hellerup, Denmark.
| | - Simone Hofman Rosenkranz
- Research and Test Center for Health Technologies, Copenhagen University Hospital, Rigshospitalet-Glostrup, Valdemar Hansens Vej 1-23, 2600, Glostrup, Denmark
| | - Anne Mielke Christensen
- Department of Cardiology, Cardiovascular Research, Copenhagen University Hospital Herlev-Gentofte, Kildegaardsvej 28, 2900, Hellerup, Denmark
| | - Morten Schou
- Department of Cardiology, Copenhagen University Hospital Rigshospitalet-Glostrup, Blegdamsvej 9, 2100, Copenhagen Ø, Denmark
| | - Christian Jøns
- Department of Cardiology, Copenhagen University Hospital Rigshospitalet-Glostrup, Blegdamsvej 9, 2100, Copenhagen Ø, Denmark
| | - Gunnar Gislason
- Department of Cardiology, Cardiovascular Research, Copenhagen University Hospital Herlev-Gentofte, Kildegaardsvej 28, 2900, Hellerup, Denmark
| | - Anne-Christine Ruwald
- Department of Cardiology, Cardiovascular Research, Copenhagen University Hospital Herlev-Gentofte, Kildegaardsvej 28, 2900, Hellerup, Denmark.,Department of Medicine, Zealand University Hospital, Sygehusvej 10, 4000, Roskilde, Denmark
| |
Collapse
|